News & Media > BHIVA statement re NICE approval of first long-acting injectable HIV-1 treatment, 18 November 2021

BHIVA statement re NICE approval of first long-acting injectable HIV-1 treatment, 18 November 2021

Thursday 18 November 2021

BHIVA welcomes the advent of injectable HIV treatment. More choice allows us to personalise medication according to need. We look forward to working with clinics to identify the people for whom this is most appropriate.

The drug is not yet available. Final NICE policy recommendations will be issued in January. The NHS then has 90 days to deliver these recommendations. The new treatment will therefore be available in April.


For further information, please contact bhiva@bhiva.org or for media enquiries, please contact Jo Josh at jo@commsbiz.com or +44 (0)7306 391875.